UK markets closed

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,643.50+14.50 (+0.89%)
At close: 06:14PM BST

GlaxoSmithKline plc

980 Great West Road
Middlesex
Brentford TW8 9GS
United Kingdom
44 20 8047 5000
https://www.gsk.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees70,212

Key executives

NameTitlePayExercisedYear born
Ms. Emma Natasha WalmsleyCEO & Director5.39M53.92M1969
Ms. Julie Belita BrownCFO & Executive Director5.14MN/A1962
Ms. Shobie RamakrishnanChief Digital & Technology OfficerN/AN/A1971
Mr. Tony WoodChief Scientific Officer and Head of R&DN/AN/AN/A
Ms. Sarah Elton-FarrHead of Investor RelationsN/AN/AN/A
Mr. James FordSenior VP & Group General Counsel of Legal & ComplianceN/AN/AN/A
Ms. Sally JacksonSenior Vice President of Global Communications & CEO OfficeN/AN/AN/A
Mr. David Simon Redfern BSc (Hons), CAPresident of Corporate DevelopmentN/AN/A1966
Ms. Diana ConradChief People OfficerN/AN/AN/A
Mr. Philip C. ThomsonPresident of Global AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Corporate governance

GlaxoSmithKline plc’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.